Treatment of hepatitis delta virus genotype 3 infection with peg-interferon and entecavir
详细信息 查看全文
- 作者：Lourdes Maria Pinheiro Borzacova ; Larissa Deadame de Figueiredo Nicoletea ; Luan Felipo Botelho Souza ; Alcione Oliveira dos Santos ; Deusilene Souza Vieira ; Juan Miguel Villalobos Salcedo ; juanitto2001@yahoo.com.br" class="auth_mail" title="E-mail the corresponding author
- 关键词：HDV ; Genotype 3 ; Treatment ; PEG-IFN ; Entecavir
- 刊名：International Journal of Infectious Diseases
- 出版年：2016
- 出版时间：May 2016
- 年：2016
- 卷：46
- 期：Complete
- 页码：82-88
- 全文大小：625 K
文摘
- •
The effects of therapy with pegylated interferon alpha 2a (PEG-IFN) were evaluated in patients with hepatitis delta virus genotype 3 (HDV-3) and these were correlated with a possible cure rate higher than expected.
- •
The therapeutic protocol used in this study presented a satisfactory response level in terms of the proportion of treated subjects with a virological response.
- •
HDV patients in the Amazon region can be treated with a combination of PEG-IFN and entecavir for 48 weeks, with a good chance of negative HDV RNA at week 24.
- •
The results suggest that HDV-3 in the native population may be an ‘easy to treat’ variant compared to HDV-1.